Pfizer (NYSE:PFE) Stock Price Down 1.4% – What’s Next?

Pfizer Inc. (NYSE:PFE) was down 1.4% during mid-day trading on Monday. The stock traded as low as $27.12 and last traded at $27.4150. Approximately 32,348,021 shares were traded during trading, a decline of 20% from the average daily volume of 40,668,301 shares. The stock had previously closed at $27.80.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s turnaround case remains a potential support for the stock. The company has reportedly delivered ten consecutive earnings beats, while declining COVID-related headwinds and a possible obesity-drug pipeline deal could provide new growth and an estimated 20% upside. Pfizer’s Turnaround Could Be Bigger Than Investors Think
• Positive Sentiment: Pfizer’s roughly 6% dividend yield and diversified pharmaceutical portfolio continue to attract income-focused investors. Some analysts argue that the company’s restructuring and pipeline investments could support firmer growth beginning in 2029 despite upcoming patent expirations. Here’s Exactly Why I’m Not Afraid of Pfizer’s 6% Dividend Yield
• Neutral Sentiment: Leerink Partners maintained a “Hold” view on Pfizer, reflecting a balance between the stock’s relatively inexpensive valuation and high yield and concerns about growth, patents and execution. Pfizer Receives a Hold from Leerink Partners
• Negative Sentiment: Florida’s attorney general sued Pfizer and CEO Albert Bourla, alleging deceptive marketing of the company’s COVID-19 vaccine and failure to disclose health risks. The litigation creates potential legal costs, reputational damage and renewed scrutiny of Pfizer’s vaccine business. Florida Attorney General Sues Pfizer for Misleading COVID-19 Vaccine Safety Claims
• Negative Sentiment: Vaxcyte’s strong vaccine-study results have highlighted a potential competitive threat to Pfizer and Merck in a market estimated at $3 billion to $6 billion. The development could raise concerns about Pfizer’s long-term vaccine market share. Vaxcyte Stock Spikes as Lead Vaccine Candidate Takes Aim at Pfizer and Merck
• Negative Sentiment: Moderna’s rally ahead of full melanoma-vaccine data has made Pfizer look less attractive by comparison, particularly as investors favor competitors with promising next-generation oncology and mRNA platforms. Moderna Surges as Full Melanoma Readout Nears

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a research report on Tuesday, June 9th. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Sunday, September 13th. HSBC upped their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, September 10th. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Monday, July 6th. Finally, BMO Capital Markets cut their price target on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $28.39.

Pfizer Stock Down 1.4%

The firm’s 50-day simple moving average is $27.41 and its 200 day simple moving average is $26.48. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The company has a market cap of $156.26 billion, a P/E ratio of 36.07, a PEG ratio of 1.87 and a beta of 0.32.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the company posted $0.78 earnings per share. The firm’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pfizer

Hedge funds have recently bought and sold shares of the company. Park National Corp OH lifted its holdings in Pfizer by 6.4% during the third quarter. Park National Corp OH now owns 257,556 shares of the biopharmaceutical company’s stock worth $7,345,000 after acquiring an additional 15,475 shares in the last quarter. Baker Tilly Wealth Management LLC grew its stake in Pfizer by 35.0% in the third quarter. Baker Tilly Wealth Management LLC now owns 12,951 shares of the biopharmaceutical company’s stock valued at $369,000 after acquiring an additional 3,361 shares during the period. Argent Capital Management LLC bought a new stake in shares of Pfizer in the third quarter worth about $8,128,000. Heartwood Wealth Advisors LLC raised its position in shares of Pfizer by 4.5% during the third quarter. Heartwood Wealth Advisors LLC now owns 75,030 shares of the biopharmaceutical company’s stock worth $2,140,000 after purchasing an additional 3,202 shares during the period. Finally, Rockland Trust Co. lifted its holdings in shares of Pfizer by 1.8% during the 3rd quarter. Rockland Trust Co. now owns 437,758 shares of the biopharmaceutical company’s stock valued at $12,485,000 after purchasing an additional 7,562 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.